Try our Advanced Search for more refined results
Abrams & Bayliss
-
Trial | Filed: May 03, 2024 | Entered: May 03, 2024 In re: Entresto (Sacubitril/Valsartan) Patent Litigation
Patent - Abbreviated New Drug Application(ANDA) | Delaware
Proposed Findings of Fact
Proposed Findings of Fact by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd.. (Taylor, Daniel) Modified on 5/3/2024 (nms).
-
Trial | Filed: May 03, 2024 | Entered: May 03, 2024 In re: Entresto (Sacubitril/Valsartan) Patent Litigation
Patent - Abbreviated New Drug Application(ANDA) | Delaware
Post Trial Brief
POST TRIAL Answering Brief on Noninfringement of the '667 Patent, by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd.. (Taylor, Daniel) Modified on 5/3/2024 (nms).
-
Trial | Filed: May 03, 2024 | Entered: May 03, 2024 In re: Entresto (Sacubitril/Valsartan) Patent Litigation
Patent - Abbreviated New Drug Application(ANDA) | Delaware
Proposed Findings of Fact
Proposed Findings of Fact by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra)
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Archive of over 450,000 articles
- Database of over 2.1 million cases
- 62,000+ organization-specific pages.
- Daily and real-time news and case alerts on organizations, industries, and customized search queries.
- Significant legal events involving law firms, companies, industries, and government agencies.
- Learn more
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login